Ripretinib (Qinlock) for GIST

Med Lett Drugs Ther. 2021 Apr 5;63(1621):e56-e57.
No abstract available

Keywords: Ayvakit; GIST; Gleevec; Qinlock; Stivarga; Sutent; adverse effects; avapritinib; dosage; drug interactions; efficacy; imatinib; lactation; pregnancy; regorafenib; ripretinib; safety; sunitinib.

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Gastrointestinal Neoplasms / drug therapy*
  • Gastrointestinal Neoplasms / enzymology
  • Gastrointestinal Neoplasms / mortality
  • Gastrointestinal Neoplasms / pathology
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Gastrointestinal Stromal Tumors / enzymology
  • Gastrointestinal Stromal Tumors / mortality
  • Gastrointestinal Stromal Tumors / pathology
  • Humans
  • Molecular Targeted Therapy
  • Naphthyridines / adverse effects
  • Naphthyridines / therapeutic use*
  • Progression-Free Survival
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Time Factors
  • Urea / adverse effects
  • Urea / analogs & derivatives*
  • Urea / therapeutic use

Substances

  • Antineoplastic Agents
  • Naphthyridines
  • Protein Kinase Inhibitors
  • Urea
  • ripretinib